| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
CD95EfferocytosisCajal bodyPML nuclear bodiesFLASHSp100| 1 | 2002 | Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. | 
| + | - | nl | Immunol Cell Biol 80(2):131-7 (2002) |
| 2 | 1999 | Cell death induced by the Fas/Fas ligand pathway and its role in pathology. |
| + | - | nl | Immunol Cell Biol 77(4):312-7 (1999) |
| 3 | 1999 | Signalling by CD95 and TNF receptors: not only life and death. |
| + | - | nl | Immunol Cell Biol 77(1):41-6 (1999) |
| 4 | 2009 | The many roles of FAS receptor signaling in the immune system. |
| + | - | nl | Immunity 30(2):180-92 (2009) Strasser A |
| 5 | 1996 | Fas-induced apoptosis, and diseases caused by its abnormality. |
| + | - | nl | Genes Cells 1(10):873-9 (1996) |
| 6 | 1998 | Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model. |
| + | - | nl | J Hum Genet 43(1):2-8 (1998) |
| 7 | 1998 | CD95 mediated T cell apoptosis and its relevance to immune deviation. |
| + | - | nl | Oncogene 17(25):3271-6 (1998) |
| 8 | 1996 | Looking beneath the surface: the cell death pathway of Fas/APO-1 (CD95). |
| + | - | nl | Mol Med 2(1):7-20 (1996) |
| 9 | 1999 | The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations. |
| + | - | nl | Arthritis Rheum 42(9):1833-42 (1999) |
| 10 | 2005 | Induction of tolerance using Fas ligand: a double-edged immunomodulator. |
| + | - | nl | Blood 105(4):1396-404 (2005) Askenasy N |
| 11 | 2009 | Tyrosine phosphorylation and CD95: a FAScinating switch. |
| + | - | nl | Cell Cycle 8(6):838-42 (2009) |
| 12 | 2007 | FLASH meets nuclear bodies: CD95 receptor signals via a nuclear pathway. |
| + | - | nl | Cell Cycle 6(7):771-5 (2007) |
| 13 | 2003 | The CD95(APO-1/Fas) DISC and beyond. |
| + | - | nl | Cell Death Differ 10(1):26-35 (2003) |
